Neoantigens and cancer-testis antigens as promising vaccine candidates for triple-negative breast cancer: Delivery strategies and clinical trials
Recommended Citation
Malla R, Srilatha M, Muppala V, Farran B, Chauhan VS, and Nagaraju GP. Neoantigens and cancer-testis antigens as promising vaccine candidates for triple-negative breast cancer: Delivery strategies and clinical trials. J Control Release 2024; 370:707-720.
Document Type
Article
Publication Date
6-1-2024
Publication Title
Journal of controlled release
Abstract
Immunotherapy is gaining prominence as a promising strategy for treating triple-negative breast cancer (TNBC). Neoantigens (neoAgs) and cancer-testis antigens (CTAs) are tumor-specific targets originating from somatic mutations and epigenetic changes in cancer cells. These antigens hold great promise for personalized cancer vaccines, as supported by preclinical and early clinical evidence in TNBC. This review delves into the potential of neoAgs and CTAs as vaccine candidates, emphasizing diverse strategies and delivery approaches. It also highlights the current status of vaccination modalities undergoing clinical trials in TNBC therapy. A comprehensive understanding of neoAgs, CTAs, vaccination strategies, and innovative delivery methods is crucial for optimizing neoAg-based immunotherapies in clinical practice.
Medical Subject Headings
Humans; Cancer Vaccines; Antigens, Neoplasm; Triple Negative Breast Neoplasms; Female; Animals; Immunotherapy; Clinical Trials as Topic; Drug Delivery Systems
PubMed ID
38744346
Volume
370
First Page
707
Last Page
720
